Syngenta Group, the Chinese-owned seed and pesticide giant, is reportedly facing fresh delays in its plans for a potential $5 billion initial public offering in Hong Kong. This setback follows previous postponements and a withdrawn Shanghai listing application in March 2024. The company, controlled by Chinese state-owned Sinochem, has been working towards a public listing for several years.
The agrochemicals company had initially aimed to apply for a Hong Kong Stock Exchange listing in the second quarter of 2026, with a target to launch the offering in the fourth quarter of the same year, subject to market conditions. Sources previously indicated that Syngenta could sell up to 20% of its shares in the IPO, potentially raising between $5 billion and $10 billion. The company has engaged banks such as CICC and Goldman Sachs to manage the offering.
The initial public offering is partly motivated by a desire to reduce Chinese ownership, which could help alleviate US concerns amid heightened trade tensions, especially after Arkansas ordered Syngenta to sell 160 acres of farmland in 2023. Proceeds from the IPO are also intended to help reduce Syngenta's net debt, which stood at $24.8 billion at the end of 2024, and to fund research and development and potential acquisitions. Syngenta typically spends approximately $2 billion annually on R&D.
Despite the recurring delays, Syngenta has seen improving financial performance. The company reported a 13% rise in earnings before interest, tax, depreciation, and amortization to $4.4 billion last year, even as sales slightly dipped by 1% to $28.4 billion after exiting lower-margin businesses. Profits also rose 25% in the first nine months of 2025, despite slightly lower sales, as the company focused on higher-margin grain trading and other segments. The company has stated its intention to return to the capital market when the time is right, signaling continued commitment to the IPO.
